IMMURON’S TRAVELAN APPROVED FOR MARKETING IN CANADA
Melbourne, Australia, 13 November 2013: Australian biopharmaceutical company Immuron Limited (ASX: IMC), today announced that its Canadian partner for Travelan®, Paladin Labs Inc., has received from Health Canada a Product License authorizing the sale of Travelan in Canada. Similarly to the Australian listing for Travelan, the authorization granted to Paladin Labs is for tablets comprising 200mg of Immuron’s anti-ETEC hyperimmune bovine colostrum. In Canada, Travelan is classified as a Natural Health Product and will be available to patients over-thecounter, without the requirement to obtain a prescription. The authorization for Travelan in Canada entitles Paladin Labs to claim
